Antibodies developed by researchers at Rensselaer Polytechnic Institute are unusually effective at preventing the formation of toxic protein particles linked to Alzheimer's disease and Parkinson's disease, as well as Type 2 diabetes, according to a new study.
The onset of these devastating diseases is associated with the inappropriate clumping of proteins into particles that are harmful to cells in the brain (Alzheimer's disease and Parkinson's disease) and pancreas (Type 2 diabetes). Antibodies, which are commonly used by the immune system to target foreign invaders such as bacteria and viruses, are promising weapons for preventing the formation of toxic protein particles. A limitation of conventional antibodies, however, is that high concentrations are required to completely inhibit the formation of toxic protein particles in Alzheimer's, Parkinson's, and other disorders.
To address this limitation, a team of researchers led by Rensselaer Professor Peter Tessier has developed a new process for creating antibodies that potently inhibit formation of toxic protein particles. Conventional antibodies typically bind to one or two target proteins per antibody. Antibodies created using Tessier's method, however, bind to 10 proteins per antibody. The increased potency enables the novel antibodies to prevent the formation of toxic protein particles at unusually low concentrations. This is an important step toward creating new therapeutic molecules for preventing diseases such as Alzheimer's and Parkinson's.
"It is extremely difficult to get antibodies into the brain. Less than 5 percent of an injection of antibodies into a patient's blood stream will enter the brain. Therefore, we need to make antibodies as potent as possible so the small fraction that does enter the brain will completely prevent formation of toxic protein particles linked to Alzheimer's and Parkinson's disease," said Tessier, assistant professor in the Howard P. Isermann Department of Chemical and Biological Engineering at Rensselaer. "Our strategy for designing antibody inhibitors exploits the same molecular interactions that cause toxic particle formation, and the resulting antibodies are more potent inhibitors than antibodies generated by the immune system."
Results of the new study, titled "Rational design of potent domain antibody inhibitors of amyloid fibril assembly," were published online last week by the journal Proceedings of the National Academy of Sciences (PNAS). The study may be viewed at: http://www.pnas.org/content/early/2012/11/14/1208797109.abstract
Rensselaer Polytechnic Institute: http://www.rpi.edu/News
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
UN assistant secretary general says deadly outbreak, which has been blamed on UN troops, demands decisive action
Caffeine is the drug many of us can't live without – but do you have any idea how much is in your daily hit?
Warmer temperatures are causing malaria to spread in the African and South American highlands, traditionally havens from the disease, scientists say.
How best to achieve success is a highly contentious issue, but politicians should remember that a good start in life is key
A second child seems to have been cleared of the AIDS virus, thanks to heavy-duty drugs started just hours after birth. This spring researchers plan to test that approach in 60 more newborns.
A report finds that azodicarbonamide wasn't just in Subway's bread: It's in hundreds of foods. While it has been linked to asthma in factory workers, the additive poses no known risk to consumers.
Army initiative to research suicides in the US military released its first three studiesAmanda Holpuch
The luxury fibre can be fashioned into screws and plates that could hold broken bones together while they heal, before biodegrading when no longer needed
Middle-aged people on a high-protein diet are at greater risk of dying from cancer, claims a study, but critics say firm evidence is lacking
In an exclusive interview with National Geographic, Nora Volkow, director of the National Institute on Drug Abuse, shares her concerns about the consequences of legalizing the drug.